WO2004041236A1 - 皮膚外用剤用組成物およびその使用方法 - Google Patents
皮膚外用剤用組成物およびその使用方法 Download PDFInfo
- Publication number
- WO2004041236A1 WO2004041236A1 PCT/JP2003/009651 JP0309651W WO2004041236A1 WO 2004041236 A1 WO2004041236 A1 WO 2004041236A1 JP 0309651 W JP0309651 W JP 0309651W WO 2004041236 A1 WO2004041236 A1 WO 2004041236A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- skin
- acid
- composition according
- mixed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to a skin external preparation containing a physiologically active ingredient containing a specific compound and a specific medicinal agent, and having excellent whitening effect and anti-aging effect.
- whitening agents such as ascorbic acid, placenta extract, daltathione, and hydroquinone have been added to prevent or ameliorate the darkening of the skin caused by sunburn and the like, and spots and sopacas caused by pigmentation.
- cell activators such as vitamin A, soybean extract, and seaweed extract are added to prevent or improve skin wrinkles and sagging caused by aging, ultraviolet exposure, etc., and decrease in elasticity. It is also a hot water extract of stems, branches, leaves, etc. or ethanol of Cistusladaniferus L., Cistuscreticus L. N Cistus mo noper 1 ensis L.
- Extracts such as hexane and hexane have strong melanin production inhibitory action, cell activating action, and antibacterial action, which are found to be activities based on labdenoic acids.
- labacid (labd-8_en_15-oicacid) has a strong inhibitory effect on melamine production, a cell activating effect, and an antibacterial effect.
- salts, methyl and ethyl ester forms, and their reduced forms also have the same activity (Japanese Patent Application Laid-Open No. 11-30219, etc.).
- An object of the present invention is to provide a skin external preparation having an excellent skin-whitening effect, particularly an excellent skin-whitening effect and / or an anti-aging effect.
- One embodiment of the present invention is: (A) the following general formula (1) :
- R 1 represents —CH 2 OH or COOR 6
- R 6 represents hydrogen, a lower alkyl group having 1 to 3 carbon atoms or a cation capable of forming a salt with COO—
- 2 to R 5 each independently represent a hydrogen atom or a methyl group
- the (B) force (B 1) asparagus extract, corn extract, soybean extract, senuki extract, age extract, raspberry extract, kujin extract, kokahi extract, Coffee extract, rice extract, wheat germ extract Exudates, saicin extract, hawthorn extract, white lily extract, peony extract, tea extract, molasses extract, grape extract, hop extract, maikai power extract, mochi power extract, wagon extract, seaweed Extracts, dibutylhydroxytoluene, butylhydroxyanisonore, mannitole, ⁇ -potency rotin, quenorecetin, quenoresitrin, rutin, vitamin ⁇ and its derivatives, genoshoko extract, saxifrage extract, sampens extract, melissa extract Products, glycyrrhizic acid and its derivatives, glycyrrhetinic acid and its derivatives, vitamin ⁇ and its derivatives, gentian
- composition of the present invention is excellent as an external preparation for skin, in particular, an external preparation for whitening or an external preparation for preventing aging.
- beautiful skin refers to, for example, suppression of pigmentation, darkening of the skin due to dull skin, sunburn, etc., prevention and improvement of spots and freckles, prevention and improvement of wrinkles, etc. Should be interpreted in the broadest sense, including “whitening” and “anti-aging”.
- the compound represented by the general formula (1) is Cistus 1 adaniierus, Cistuscreticus L., Cistus mo noper liens Ls. a compound extracted from one or more plants selected from the plant group consisting of ⁇ stussa 1 vifo 1 ius, or the composition as a compound prepared from the compound; and the general formula (1) , C istusladaniierus, C istuscreticus L., C istus mo noperiensis L., and the like. the composition comprising one or more extracts selected from a plant group consisting of istusssalvifo1ius;
- the present invention provides a method for inhibiting melanin production, which comprises applying the composition to the skin; a method for whitening the skin, comprising applying the composition to the skin; A method for preventing skin aging including application to the skin; a method for using the composition as an external preparation for skin; a method for using the composition for producing an external preparation for skin; represented by the general formula (1)
- And at least one compound of the compound represented by the general formula (1) which comprises one or more members selected from the group consisting of the above-mentioned medicinal agents.
- composition of the present invention is applied to a skin external preparation.
- the external preparation for skin of the present invention contains one or more physiologically active components (hereinafter, referred to as “component (A)”) of a compound represented by the following general formula (1).
- 11 represents 1 ⁇ 001 or 001 ⁇ 6
- R 6 is hydrogen, a lower alkyl group having 1 to 3 carbon atoms, or a cation capable of forming a salt with COO—.
- the lower alkyl group having 1 to 3 carbon atoms may be linear or branched. Examples of the alkyl group include a methyl group, an ethyl group, an n-propyl group, and an isopropyl group.
- the cation capable of forming a _COO- and salts N a +, include K + and cations of NH 4 + and the like.
- the compound represented by the general formula (1) can be extracted from plants. Extracts from plants are commercially available (Rabdanum Absolute, manufactured by Givaudan, etc.), and commercial products can also be used in the present invention. Furthermore, as an extract, R 1 — After obtaining an acid that is COOH, it can be used as component (A) after converting it into an ester, reduced form or salt such as methyl and ethyl.
- the type of plant from which the compound represented by the general formula (1) is extracted is not particularly limited as long as it is a plant containing the compound, but in particular Cistusladaniferus L. s Cistuscret ICUS L. It is advantageous to use plants of Cistus mo noperiensis 1L., Cistussalvifoli us (Coleoptera). These can be used alone or in combination of two or more.
- the extraction site of the plant is not particularly limited, and can be extracted from leaves, branches, bark, and the like. Further, the extraction operation may be performed immediately after each part is collected, or the extraction operation may be performed after each part is collected and dried.
- the extraction method is desirably performed using one or more solvents selected from water, lower alcohols, petroleum ethers and hydrocarbons.
- lower alcohol means that the carbon number is
- Alcohols of 1 to 4 are preferred, and methyl alcohol and ethyl alcohol are particularly preferred.
- Well-known petroleum ethers can be used, and commercially available petroleum ethers can also be used.
- the hydrocarbon solvent include aliphatic hydrocarbons, alicyclic hydrocarbons, and aromatic hydrocarbons that are liquid at ordinary temperature, and particularly preferred are aliphatic hydrocarbons and aromatic hydrocarbons that are liquid at ordinary temperature. And hydrocarbons such as hexane and toluene are preferred.
- the extraction operation varies depending on the type of the plant and the solvent to be used, but can usually be performed by immersing the cut plant in the solvent at a temperature of room temperature to 50 ° C. During the immersion, the solvent may be gently agitated. Further, a device such as a well-known Soxhlet extractor may be used. The time required for extraction is usually about 3 to 48 hours.
- extraction can be performed by steam distillation or boiling in hot water. In this case, it is obtained by scooping up the gum floating on the water by steam distillation or hot water extraction, and separating it from insolubles with the solvent used for the extraction. Obtained in this way
- the extract contains 25-35% by mass (hereinafter simply referred to as “%”) of labdenoic acids.
- the crude extract or the commercially available extract from the plant can be used as it is as the component (A).
- the crude extract or the commercially available extract may further comprise a compound represented by the general formula (1).
- the following is a crude dough containing a mixture of love do 7—one 15—Oic acid, love one 8 (1 7) —one one 15—oit acid, loved—8—one one 15—oic acid.
- a typical example of a method for purifying each component from an extract or a commercially available product will be described, but the present invention is not limited to the following method.
- the crude extract or a commercially available extract is subjected to molecular distillation under reduced pressure of 0.1 to 0.5 mmHg, and the fractions from 160 ° C to 230 ° C are collected.
- the component (A) a mixture of these acids may be used as it is, or if necessary, an ester, a salt, or a reductant such as methyl or ethyl is prepared, and then the mixture is used. You can also.
- this acid mixture is dissolved in ethanol, reacted in the presence of a catalytic amount of sulfuric acid to form an ethyl ester, and then subjected to silica gel chromatography using silver nitrate-treated silica gel. Wash the column with hexane and elute with 1% ethyl acetate-hexane.
- Rabdo 1-8-Enic 1-5 Eic acid ethyl ester elutes, followed by Rabdo 7_Oen-Ic 1-15—Oic acid ethyl ester, Rabdo 1 8 (1 7) —En 1 1 Eluted in the order of 5—Oic Acid Dethyl Ester.
- the solvent is distilled off to obtain a pure product of each ethyl ester. From the obtained ethyl ester, a free acid can be obtained by hydrolysis. Furthermore, a methyl ester can be obtained by reacting a free acid with diazomethane.
- the thus obtained extracts of branches, leaves, etc. such as C istus 1 adaniferus belonging to the family Candidae, C istusmonoperiensis L. C istussalvifolius, and the extracts obtained from the extracts Acids, methyl esters, ethyl esters, or mixtures of two or more thereof can be used as the component (A) of the present invention.
- component (i) stems, branches, and leaves of Cistusladaniferus L., Cistuscreticus L., Cistus mo noperiensis L., Cistussalvifolius belonging to the family Crabaceae Hot water extract or organic solvent (ethanol, hexane, etc.) extract, etc .;
- Rabdo obtained by molecular distillation of the extract of (i) or crude labdenoic acid.
- Oic acid (labd—7_en—15—oicacid), Rabdo-1 8 (1 7) —Yen-15-Oic acid (labd—8 (17) —en—15_o_icacid) and Rabdo-1 8—
- 15-Oic acid (1 abd-8_en-15-oicacid); (iii) a salt or a methyl or ethyl ester of the acid of (ii); or (iv) )
- An external preparation for skin which is the reduced form of the above (iii).
- the content of the compound represented by the general formula (1) in the skin external preparation of the present invention is preferably 0.000001 to 5%, more preferably 0.0001 to 2%, as a dry solid content.
- the plant extract can be stably compounded, and can exhibit excellent skin effect (particularly, whitening and anti-aging effects).
- the concentration of the extract is not limited at all if the content of the dry solid content as a solute is within the above range.
- the component (B) combined with the component (A) is one or more selected from the following agents.
- “derivative” includes an ester salt.
- (B1) an asparagus extract, a corn extract, a soybean extract, a rose extract, an age extract, a strawberry extract, a kujin extract, a gokahi Extract, coffee extract, komenu power extract, wheat germ extract, saicin extract, hawthorn extract, syllium extract, peony extract, tea extract, molasses extract, grape extract, hop extract, Maikai power extract, mocca extract, ozone extract, seaweed extract, dibutylhydroxytoluene, butylhydroxyanisonole, mannitol,] 3-carotene, quenorecetin, quercitrin, rutin, vitamin E and its derivatives, genoshoko Extract, snowy nosita extract, sampens extract, melissa extract, glycyrrhichi Acid and its derivatives, glycyrrhetinic acid and its derivatives, vitamin B and its
- (B 1) component asparagus extract, corn extract, soybean extract, senuki extract, edible extract, raspberry extract, kujin extract, gokahi extract, coffee extract, rice extract power, Wheat germ extract, saicin extract, hawthorn extract, white lily extract, peony extract, tea extract (extracts of green tea, black tea, oolong tea, etc.), molasses extract, grape extract, hop extract, Maikai power
- the extract, mocca extract, ozone extract and seaweed extract (referred to as the (C1) component) alone exhibit a medicinal effect mainly as a whitening agent, but when used in combination with the component (A), It has excellent whitening and / or anti-aging effects that cannot be obtained when used alone. More preferred are wheat germ extract, white lily extract, soybean extract, tea extract (extracts of green tea, black tea, oolong tea, etc.), grape extract, oegone extract, and seaweed extract. .
- component (B1) dibutylhydroxytoluene, butylhydroxyaniso monole, mannitol, ⁇ -carotene, quenorecetin, quenolecitrin, noretin, vitamin ⁇ and derivatives thereof (d 1 - ⁇ ( ⁇ , ⁇ )) Tocopherol, d1- ⁇ -tocopherol acetate, d1- ⁇ -tocopherol nicotinic acid, d1- ⁇ -tocopherol linoleic acid), genochocolate extract, Saxifrage extract, Sampens extract and Melissa extract ( (1) component) alone exhibits its efficacy mainly as an antioxidant, but when used in combination with the above-mentioned component (ii), excellent whitening and aging or antiaging can not be obtained when used alone. It works. Even more preferred are vitamins and their derivatives, dibutylhydroxytoluene, —carotene, rutin, and saxifrage extracts
- glycyrrhizic acid and its derivatives glycyrrhetinic acid and its derivatives, vitamin ⁇ and its derivatives, gentian extract, dokudami extract, button extract, aloe extract, Alniki extract, and Otogiriso extract Things, Oba Extract, kingin extract, salvia extract, birch extract, perilla extract, mugwort extract, bonito extract, comfrey extract, ju extract, watercress extract, tokinsen extract, nitco extract , Hoo extract, Mukuroji extract, Eucalyptus extract and Vetchus extract (these are referred to as the (E1) component) alone show efficacy mainly as an anti-inflammatory agent, but are used in combination with the (A) component As a result, excellent whitening and / or anti-aging effects are obtained that cannot be obtained when used alone.
- glycyrrhizic acid and its derivatives More preferred are glycyrrhizic acid and its derivatives, glycyrrhetinic acid and its derivatives, aloe extract, opac extract, kingin extract, perilla extract, potato extract, comfrey extract and ju extract. No.
- vitamin A and its derivatives retinol palmitate, retinol acetate, etc.
- tartaric acid malic acid, glycolic acid, succinic acid, serine, glutamic acid, hydroxyproline, theanine, pyrrolidone carboxylic acid Acid, Eucommia moss extract, soybean extract, carrot extract, barley extract, beech extract, Ginkgo biloba extract, arboreal extract, yeast extract, lactic acid extract and bifidobacterium extract ( F 1) component alone exhibits a medicinal activity mainly as a cell activator, but when used in combination with component (A), it does not provide excellent whitening and aging when used alone. It has a preventive effect. More preferred are vitamin A and its derivatives, hydroxyproline, carrot extract, barley extract, beech sprouts extract, Ginkgo biloba extract, arboreal extract and yeast extract.
- the component (B1) 2-hydroxy-14-methoxybenzophenone, 2-hydroxy-4--4-methoxybenzophenone-15-sulfonic acid, 2-hydroxy-14-methoxybenzophene Sodium non-5-sulfonate, paramethoxy cinnamate 1,2-ethynolehexyl and 4-tert-butyl-4'-methoxydibenzoinolemethane (these are referred to as the (G1) component), alone or mainly, prevent UV rays. Although it shows a medicinal effect as an agent, when used in combination with the component (A), it exhibits excellent whitening and / or anti-aging effects that cannot be obtained when used alone.
- 2-hydroxy-4-phenoxybenzophenone 2-hydroxy-4-methoxybenzophenone-15-sulfonate, sodium parasulfate, 2-methoxyethyl cinnamate, 4-tert-hexanol —Butinole _ 4 '—Methoxydibenzoinolemethane.
- Altea extract Altea extract, Shobu extract, Zio extract, Malo Yue extract, Zeniaoi (Usbeyutachioi) extract, Apricot extract, Lime extract, Raspberry extract, Almond extract, Tomato extract, phospholipids and derivatives thereof (eg, soybean phospholipid, hydrogenated soybean phospholipid, hydrogenated soybean lysolin lipid, hydrogenated egg yolk lecithin, egg yolk lecithin, egg yolk lysophosphatidylcholine, etc.), amatija extract,
- the coltsfoot extract and quince seed extract (these are referred to as the (HI) component) alone exhibit a medicinal effect mainly as a humectant.
- the extract when used in combination with the component (A), the extract is obtained when used alone. It has excellent whitening and aging or anti-aging effects. More preferred are phospholipids and derivatives thereof, Amatilla extract, Zeniaoi extract, coltsfoot extract and Quincyd extract.
- the skin external preparation containing one or more selected ones is excellent as a skin whitening external preparation.
- the amount of the component (B1) in the external preparation for skin of this embodiment varies depending on the type (component (C1) to component (HI)), but is preferably in the following range. Within this range, when combined with the component (A), it does not affect the stability over time of the drug product and the component (A) in the drug product, and has a higher skin effect (particularly, whitening and whitening). Can exhibit an anti-aging effect).
- the compounding amount of the component (C1) in the skin external preparation of this embodiment is preferably from 0.0001 to 10%, and more preferably from 0.0001 to 5%.
- the dry solid content may be within this range. Within this range, a skin external preparation exhibiting a superior whitening effect and having a good feeling upon use can be obtained.
- the amount of the component (D1) in the external preparation for skin of this embodiment is preferably 0.0001 to 5%, more preferably 0.0001 to 3%.
- the extract is used as it is as the extract, it may be in this range as a dry solid content. Within this range, a more excellent antioxidant effect is exhibited, and an external preparation for skin that exhibits excellent whitening and / or anti-aging effects and has a good feeling upon use can be obtained.
- the compounding amount of the component (E1) in the skin external preparation of this embodiment is preferably 0.0001 to 5%, more preferably 0.0001 to 3%.
- the extract may be in this range as a dry solid content. Within this range, an excellent anti-inflammatory effect can be seen, an excellent whitening and Z or anti-aging effect can be obtained, and a skin external preparation with a good feeling upon use can be obtained.
- the compounding amount of the component (F1) in the skin external preparation of this embodiment is preferably 0.0001 to 5%, more preferably 0.0001 to 3%.
- the dry solid content may be within this range. Within this range, a more excellent skin roughness improving effect is exhibited, an excellent whitening and / or anti-aging effect is exhibited, and a skin external preparation having a good feeling in use can be obtained.
- the compounding amount of the (G1) component in the skin external preparation of the present embodiment is preferably 0.001 to 30%, more preferably 0.01 to 25%. Within this range, a more excellent ultraviolet ray-preventing effect is exhibited, and a skin external preparation exhibiting excellent whitening and Z or anti-aging effects and having a good feeling in use can be obtained.
- the compounding amount of the (HI) medicinal agent in the skin external preparation of the present embodiment is preferably 0.001 to 25%, more preferably 0.01 to 20%.
- the dry solid content may be within this range. More excellent in this range An excellent external moisturizing effect, an excellent whitening and Z or anti-aging effect, and a skin external preparation with a good feeling in use can be obtained.
- the component (B) includes: (B2) a Kanzo ⁇ extract, an okuinin extract, a black liquor (Krofusasdari) fruit extract, a Sempukuka (Oda Luma) extract, a cranberry fruit extract
- a Kanzo ⁇ extract a Kanzo ⁇ extract
- an okuinin extract a black liquor (Krofusasdari) fruit extract
- a Sempukuka (Oda Luma) extract a cranberry fruit extract
- This containing at least one member selected from the group consisting of an extract, a birch extract, a birch sap, a yasazi extract, a cactus extract, an arhat extract, astaxanthin and its derivatives, and a rutin derivative.
- the Kanzo extract which can be used in the present invention is extracted from a root or rhizome (herbal medicine name, licorice, Kanzo) of a plant belonging to the genus Kanzo (Glycyrrhizaglabra L.) or its congener with a suitable solvent. Is what you get.
- An oil-soluble extract obtained by extracting a Canzo from China, Russia, etc. with a hydrophobic organic solvent is more preferable.
- the okuninin extract that can be used in the present invention is suitable for seeds (crude drug name * okuinin) from the seeds of the barley (Co 11 acr yma—j ODIL. Var. Ma—yuen 3 ⁇ 4 tapf) of the genus Juzudama (Poaceae). It is obtained by extraction using a suitable solvent.
- a black currant fruit extract that can be used in the present invention is obtained by extracting the fruits of the currant blackcurrant of the family Currantaceae (Japanese name: black currant, French name: cassis, Ribesnigrum L.) using an appropriate solvent. The resulting fruit extract or the fruit juice obtained by pressing.
- the extract of Sempukuka (Odharma) that can be used in the present invention can be extracted using a suitable solvent, such as the head flower (herbal medicine name, rotted flower) of Odulma (Inulabrita nnica L.) of the genus Asteraceae. It is obtained by doing.
- a suitable solvent such as the head flower (herbal medicine name, rotted flower) of Odulma (Inulabrita nnica L.) of the genus Asteraceae. It is obtained by doing.
- the cranberry fruit extract that can be used in the present invention is the fruit of the cranberry genus of the Rhododendron family Asteraceae (Japanese name: Nornokeberry, Va ccini um ma crocorpon A iton or Va ccini um oxycoccus).
- Cake extract that can be used in the present invention is a legume plant, such as Miso bean (S patholobussuberectus), white flower oil Gonto (Mu cunabir dwo odiana), Hama force yumatu (Muc un abir dwo odiana Tu tcher), Appropriate from Milletia dierciana (Chinese name perfume tofu, Mi 11 etiadielsiana Harms) or stalk of Ryohaiwa tofu (Mi 11 etianitida Benth) (herbal medicine name: chicken blood wisteria) It is obtained by extraction using a solvent.
- Miso bean S patholobussuberectus
- white flower oil Gonto Mo cunabir dwo odiana
- Hama force yumatu Moc un abir dwo odiana Tu tcher
- Appropriate from Milletia dierciana Choinese name
- the birch sap which can be used in the present invention is birch (Betu 1 aplatyphylla S ukatc hu vvar. Japonica Ha ra, B. platyphylla S ukatchuv), birch (B. Erma ni Cham.) Gizobi campa (B. g 1 obispica Shirai), daidaimiba (B. Maxi mow icziana Rege 1), silver perch (B. pendula Roth), sweet perch (B. 1 enta 1 L.), etc. It is a liquid that overflows by piercing the trees before the flowering and leafing stages of the trees.
- the yashaji extract which can be used in the present invention includes Alnu ssieboldiana Mats um. And Alshanu (A1nusfirma Sieb. Et Zucc.) Of the birch family Alnus. nushirsuta Tu rc z.) and the fruits of a consanguineous plant, Yashaji (Miya Yasha, Minami Yasha), obtained by extraction with an appropriate solvent.
- the cactus extract that can be used in the present invention may be any extract obtained from a plant of the family Cactaceae.
- a cactus extract Op untiaficus- indica (L.) Mill, or Op untiadillenii Haw
- a suitable solvent Extracted from the stems, roots, fruits, etc. of Op untia S treptacantha using a suitable solvent.
- the extract of the Arkan fruit extract that can be used in the present invention is obtained by drying the fruit (Chinese name * Arkan fruit) of the fruit of the moromoli gross henori (Momo rdicagrosvenorii Swing 1 e) of the genus Periaceae, i. It is obtained by extraction using
- Astaxanthin and its derivatives that can be used in the present invention can be obtained by extracting a natural product such as krill, salmon, mass, Fussou grass, red yeast or the like using a suitable solvent, or by chemical synthesis. For example, extraction is performed by adding an extraction solvent to krill (Euphausiasimi 1 is GO, etc.), and extracting this solution with an astaxanthin extract obtained by filtration and further distilling the extraction solvent from this extract. Using purified astaxanthins that have been deodorized and purified by means of molecular distillation or column chromatography or high-performance liquid chromatography after performing a chemical reaction such as hydrogenation or hydrolysis. Can be. Astaxanthin is a carotenoid represented by the following formula. Derivatives thereof include monoesters selected from fatty acid esters of astaxanthin and diesters of the same or different types.
- Rutin derivatives that can be used in the present invention include, but are not limited to, rutin contained in natural products such as flowers 1f of Leguminosae (Sophorajaponica L.) and F / G (F agopyrumescu 1 entum Mo ench) of Longiaceae. What is necessary is just to improve water solubility.
- ⁇ -darcosyrutin represented by the following general formula, which is obtained by mixing rutin with a starch substance such as dextrin, and transferring enzymatic reaction to rutin such as glucose, manoletose, manoleto triose, manoleto tetraose, etc., represented by the following general formula, is preferably used.
- a rutin derivative having a noretin content of 10 to 80% is preferable. Also, These can be used alone or in combination of two or more.
- R represents gnorecose, maltose, manoletotriose or maltotetraose.
- Examples of the extraction solvent used for preparing the component belonging to the group (B 2) include water, lower monohydric alcohol (methyl alcohol, ethyl alcohol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc. ), Liquid polyhydric alcohols (glycerin, etc.), hydrocarbons (benzene, hexane, pentane, etc.), ketones (acetone, methyl ethyl ketone, etc.), ethers (getyl ether, tetrahydrofuran, dipropyl) Ether) and acetonitrile, and one or more of them can be used.
- lower monohydric alcohol methyl alcohol, ethyl alcohol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.
- Liquid polyhydric alcohols glycerin, etc.
- hydrocarbons benzene, hexane, pentane, etc.
- extraction is performed for 1 to 5 days at room temperature or by heating using ethyl alcohol or 1,3-butylene glycol having a water content of 0 to 100 Vo 1%. Then, filtration is performed, and the obtained filtrate is left to age for about one week, and then filtered again.
- a Kanzo extract, a koninin extract, a black potato (Krofusadari) fruit extract, a sempukuka (odalma) extract, a cranberry fruit extract, a cake extract, a cactus extract, a Lohan fruit extract and Dastaxanthin and its derivatives (these are referred to as (C 2) components) have a medicinal effect as a whitening agent even when used alone.
- a Kanzo extract, a koninin extract, a black potato (Krofusadari) fruit extract, a sempukuka (odalma) extract, a cranberry fruit extract, a cake extract, a cactus extract, a Lohan fruit extract and Dastaxanthin and its derivatives (these are referred to as (C 2) components) have a medicinal effect as a whitening agent even when used alone.
- the above-mentioned component (A) they can be obtained when used alone. No, it has excellent whitening and Z or anti
- the kanzo extract, the cake extract, the yashaji extract, the arhat extract, the astaxanthin and its derivatives, the rutin derivative (referred to as the component (D 2)) may be used alone. Although it shows a pharmacological effect as an antioxidant, it exhibits excellent whitening and / or anti-aging effects that cannot be obtained when used alone, when used in combination with the component (A).
- the extract of liquorice and the extract of cake cake (referred to as the component (E 2)) alone show a medicinal effect as an anti-inflammatory agent.
- the component (A) when used together with the component (A), Excellent whitening and anti-aging effects that cannot be obtained when used alone.
- cactus extract, arhat extract, astaxanthin and its derivatives and rutin derivatives (referred to as the (F 2) component) alone have a medicinal effect as a cell activator.
- the component (A) When used in combination with the component (A), excellent whitening and Z or anti-aging effects, which cannot be obtained when used alone, are exhibited.
- (B 2) component kanzo ⁇ extract, yokuinin extract, black potato (Krofusasdari) fruit extract, Sempukuka (odalma) extract, cranberry fruit extract, cake extract, birch sap, yashaji extract, cactus
- the extract and Arkanka extract (these are referred to as (G 2) components) exhibit a medicinal effect as a humectant even when used alone.
- they can be obtained when used alone. No, it has excellent whitening and / or anti-aging effect.
- the preferred amount of the component (B) in the external preparation for skin of the present invention varies depending on the type (component (C) to component (G)), but is generally preferably in the following range. Within this range, when combined with the component (A), it does not affect the stability of the preparation and the component (A) in the preparation over time, and has a higher skin effect (particularly, a whitening and / or anti-aging effect). ) Can be demonstrated.
- the components having multiple medicinal effects have been repeatedly illustrated as the components (C 2) to (G 2).
- the widest range is the preferred blending amount. Range.
- the blending amount of the component (C2) in the skin external preparation of this embodiment is preferably from 0.0001 to L O%, and more preferably from 0.0001 to 5%.
- the dry solid content may be within this range.
- a skin external preparation having a more excellent whitening and / or anti-aging effect and a good feeling upon use can be obtained.
- the amount of the component (D2) in the external preparation for skin of this embodiment is preferably 0.0001 to 5%, more preferably 0.0001 to 3%.
- the extract When the extract is used as it is as the extract, it may be in this range as a dry solid content. Within this range, a more excellent antioxidant effect is observed, and an external preparation for skin that exhibits excellent whitening and / or anti-aging effects and has a good feeling upon use can be obtained.
- the amount of the component (E2) in the skin external preparation of this embodiment is preferably 0.0001 to 5%, more preferably 0.0001 to 3%.
- the extract may be in this range as a dry solid content. Within this range, an excellent anti-inflammatory effect is observed, an excellent whitening and / or anti-aging effect is exhibited, and a skin external preparation having a good feeling upon use can be obtained.
- the compounding amount of the (F2) component in the skin external preparation of this embodiment is preferably 0.0001 to 5%, and more preferably 0.0001 to 3%.
- the dry solid content may be within this range. Within this range, a more excellent skin roughness improving effect is exhibited, an excellent whitening and / or anti-aging effect is exhibited, and a skin external preparation having a good feeling in use can be obtained.
- the compounding amount of the (G2) medicinal agent in the skin external preparation of this embodiment is preferably 0.00:! To 25%, more preferably 0.01 to 20%.
- the dry solid content may be within this range. Within this range, a more excellent moisturizing effect is exhibited, and an external preparation for skin that exhibits excellent whitening and Z or anti-aging effects and has a good feeling in use is obtained.
- the external preparation for skin of the present invention comprises the essential components (A) and ( It can be prepared by blending the B component with various types of bases known as ordinary skin external preparations.
- Examples of the form of the external preparation for skin are not particularly limited, and include, for example, milky lotions, creams, lotions, packs, detergents, makeup cosmetics, dispersions, ointments, liquids, aerosols, patches, and cataplasms. And cosmetics in any form such as a liniment and a topical medicine.
- the skin external preparation of the present invention includes various components usually used in cosmetics, quasi-drugs, external medicines, and the like, that is, water, alcohol, oils, surfactants, and the like.
- a thickener, a powder, a chelating agent, a pH adjuster, various medicinal agents, an extract derived from animals, plants and microorganisms, a fragrance, and the like can be appropriately added as long as the effects of the present invention are not impaired. Specific examples are shown below.
- a monohydric alcohol such as ethyl alcohol
- a polyhydric alcohol such as glycerin or 1,3-butylene glycol
- dissolving, refreshing, preserving, moisturizing, etc. as long as it does not overlap with the essential components.
- a monohydric alcohol such as ethyl alcohol
- a polyhydric alcohol such as glycerin or 1,3-butylene glycol
- Oils can be used regardless of their origin and properties to improve usability and usability.
- liquid paraffin squalane, triglyceride oil, ester oil, waxes, fatty acids, higher alcohols, silicone oil, fluorine-based oil, various types of wax, and the like.
- Surfactants are used for emulsification and solubilization of oils and the like, and anionic, cationic, nonionic and amphoteric activators can be used.
- carboxyvinyl polymer As the thickener, carboxyvinyl polymer, carrageenan, agar, xanthan gum, dextrin fatty acid ester, organically modified clay mineral, etc., can be used irrespective of chemical synthetic products or natural sources. Further, these components can be used not only for adjusting the viscosity of the system, but also for gelling, moisturizing, forming a film, and the like.
- a compounded or surface-treated one may be used in order to improve usability and usability.
- Inorganic powders such as talc, myriki, sericite, and silicic acid, and organic such as nylon powder Powder, fish scale foil, pearl pigments such as bismuth oxychloride, inorganic pigments such as iron oxide, carbon black, ultramarine blue, tar pigments and their lakes, natural pigments, titanium oxide, fine titanium oxide, zinc oxide, fine zinc oxide, etc. Is used depending on the application. In particular, it is preferable to include fine-particle titanium oxide / fine-particle zinc oxide since the effects of the present invention can be further enhanced.
- a chelating agent such as EDTA and a pH adjuster using a buffer such as sodium lactate-lactate can be used.
- Medicinal agents include vitamins, hormones, and various extracts, including extracts from animals, plants and microorganisms.
- Antibacterial agents are used for the purpose of preventing and improving acne, and include benzoic acid, sodium benzoate, paraoxybenzoate, parachloromethcresol, benzalkonidum chloride, phenoxyethanol, and isopropylmethylphenol. Can be By combining these, pigment deposition due to bacterial skin inflammation such as acne can be suppressed, and a higher whitening and Z or skin beautiful effect and an antiaging effect can be exhibited.
- Active oxygen scavengers are used to suppress the production of lipid peroxides due to ultraviolet rays, etc., and are used to remove superoxide dismutase, force techin and its derivatives, thiamines (thiamine hydrochloride, thiamine sulfate), riboflavins ( Vitamins such as riboflavin, riboflavin acetate, etc.), pyridoxines (pyridoxine hydrochloride, pyridoxine dioctanoate, etc.), and nicotinic acids (nicotinic acid amide, benzyl nicotinate, etc.)
- proteins or their derivatives or hydrolysates and their salts include proteins or their derivatives or hydrolysates and their salts (collagen, elastin, keratin, etc.), mucopolysaccharides and their derivatives (hyaluronic acid, Chondroitin sulfate, etc.), amino acids and their derivatives (histidine, serine, glycine, thea Nin, aspartic acid, arginine, pyrrolidone carboxylic acid, etc.), sugars (sorbitol, erythritol tonole, trehalose, inositole, gnorecose, xylitol, sucrose and its derivatives, dextrin and its derivatives, honey, etc.), D- Panthenol and its derivatives, glycolipids, ceramides, ashitapa extracts, avocado extracts, hot spring water, Usveniaoi extract, odricosoii extract, ononis extract, oats
- agents having a skin surface sealing effect jojoba oil, macadamia nut oil, olive oil, apricot oil, persic oil, safflower oil, sunflower oil, avocado oil, meadow home oil, camellia oil, almond oil , Sesame oil, sesame oil, borage (borage) oil, cocoa butter, shea butter, etc.
- jojoba oil macadamia nut oil, olive oil, apricot oil, persic oil, safflower oil, sunflower oil, avocado oil, meadow home oil, camellia oil, almond oil , Sesame oil, sesame oil, borage (borage) oil, cocoa butter, shea butter, etc.
- the names in parentheses indicate other names of plants, crude drug names, etc.).
- Blood circulation enhancers are used for the purpose of promoting melanin excretion by promoting blood flow through the skin, and include pepper tincture, ⁇ -oryzanol, and the like, and enzymes include lipase, papain, and the like. By blending them, a higher whitening and / or beautiful skin effect can be exhibited.
- Example 1 Production of Cistus 1 adaniferus L. extract Leaf and twig of Cistusladaniferus L. 2 Oil was removed from OKg by steam distillation. Thereafter, the extract obtained by extraction with 20 g of n-hexane was distilled under reduced pressure to remove low-boiling substances, thereby obtaining 150 g of a solid-paste extract.
- Example 2 The Rabuden acids and methyl esters and (manufactured by Givaudan Corp.) preparation Commercially available Love Dunham Absolute Echiruesuteru 10 8 molecularly distilled under reduced pressure (0. lm mHg), distilled until 180 ° C ⁇ 220 ° C Minutes (4.3 g) were collected. This fraction contains Compound 1 (Rabdo 1-8—15—Oic Acid), Compound 4 (Rabdo 7—15—Oic Acid), and Compound 7 (Rabdo-8 (1 7) — _ 15 _ Oic acid) (this mixture is hereinafter referred to as an acid mixture).
- the above ethyl ester mixture was subjected to silica gel chromatography to separate three kinds of acids. Specifically, 10 g of the ethyl ester mixture was dissolved in 10 OmL of hexane, injected into a silica gel column treated with silver nitrate, then injected with a solvent and eluted. The injected solvent was hexane at first, and then a mixed solvent obtained by adding 1 Vo 1% of ethyl acetate to hexane.
- compound 3 (Rabdo 8-1-15-Oic acid ethyl ester) eluted, followed by compound 6 (Rabdo 7-1-15 _ Oic acid ethyl ester, compound 9 (Rabdo acid ethyl ester).
- the solvent was distilled off from each eluate, and the pure product of each ethyl ester (0.83 g, 0 in the order of elution) 16 ⁇ and 0.63 g)
- the obtained ethyl ester was obtained by a conventional method. Hydrolysis gave the free acid. Further, a diazomethane ether solution was added dropwise to the free acid, and the solvent was distilled off to obtain a methyl ester.
- B16 melanoma cultured cells from mice were used. An appropriate amount of a MEM medium containing 10% FBS was taken in two 6-well plates, B16 melanoma cells were inoculated, and allowed to stand at 37 ° C and a carbon dioxide concentration of 5 Vo 1%. The next day, the Cistus 1 adaniferus L.
- Example 1 extract obtained in Example 1 and the labdenoic acids and their methyl and ethyl esters obtained in Example 2 were added to final concentrations of 0 (control), 5, 10 ⁇ g mL, and A sample preparation solution was added to a whitening agent, Shirahuri extract (manufactured by Maruzen Pharmaceutical Co., Ltd.), so as to have a concentration of 0, 100 gZmL, and mixed.
- Shirahuri extract manufactured by Maruzen Pharmaceutical Co., Ltd.
- the medium was replaced, and the sample preparation solution was added again.
- the medium was removed, and the cells of one plate were washed with a phosphate buffer (pH 7) and collected, and the whitening degree of the B16 melanoma cultured cells was evaluated according to the following criteria.
- Jokinin extract contains 10 g of Jokinin (JP), 70 V o 1% water-containing ethyl After adding 10 OmL of alcohol, the mixture was extracted at room temperature for 3 days, and then filtered. At this time, the dry solid content of the extract was 0.8%.
- Soil slightly white compared to control.
- a panel of 15 women aged 27 to 54 per test cream Apply the appropriate amount of the test cream to the face daily, 12 weeks, twice a day, morning and night after washing the face.
- the evaluation was based on criteria. The evaluation results are shown by the number of panelists who correspond to each evaluation.
- Human neonatal fibroblasts NB 1 RGB were used. An appropriate amount of the medium was placed in a 24-well plate, and fibroblast NB1RGB was inoculated and allowed to stand at 37 ° C in a carbon dioxide concentration of 5 vol 1%. The next day, the Cistusladaniferus L. extract obtained in Example 1, the labdenoic acids and their methyl esters and ethyl ester obtained in Example 2 were used at final concentrations of 0 (control), 5, 10 ⁇ g ZmL, and a cell activator. The sample preparation solution was added and mixed so that the carrot extract (Maruzen Pharmaceutical Co., Ltd.) had a volume of 0, 1 ⁇ g ZmL.
- the medium On the fourth day of the culture, the medium was replaced, and the sample preparation solution was added again. On the next day, the medium was removed, and the cells were washed with a phosphate buffer, collected, and the number of fibroblasts NB 1 RGB grown in each sample preparation was evaluated as the cell growth rate compared to the control. .
- soybean extract (100 zg / mL), which is already known to have a cell activating effect as a comparative example.
- the soybean extract was obtained by adding 100 mL of 70 V o 1% aqueous ethyl alcohol to 10 g of soybean seeds, extracting at room temperature for 3 days, and then filtering. At this time, the dry solid content of the soybean extract was 0.5%.
- the plant extract was found to have a cell activating ability against NB 1 RGB, a fibroblast derived from a newborn human, but it was a cell activating agent. Have better cell activating ability when used together with carrot extract Was observed. Therefore, the cell activator of the present invention exerts an extremely excellent anti-aging effect by applying to the skin a mixture of Cistusladaniferus L. extract, labdenic acid and its methyl ester, and ethyl ester and carrot extract. It is expected to effectively improve skin wrinkles and sagging caused by aging and UV exposure.
- components (1) to (6) and (10) were mixed, and a part of component (15), which was heated and maintained at 70 ° C, was added to the mixture which was heated and maintained at 70 ° C. added.
- the components (7) to (9) and (11) to (14) were mixed with this, and then cooled to obtain a cream.
- the obtained cream was examined for the effect of improving wrinkles by the following test method. .
- a panel of 20 women aged 35 to 59 per test cream was applied to the face twice daily, morning and night, for 12 weeks after washing the face.
- the wrinkle improvement effect of the coating was evaluated according to the following criteria.
- the obtained facial cleanser was excellent in stability over time, and was applied to the skin to give a clear and beautiful skin.
- the following components (13) to (17) are heated and mixed and maintained at 70 ° C., and the components (1) to (12) are similarly heated and mixed, and emulsified. After cooling, the components (18) to (25) were added, and the mixture was mixed uniformly to obtain an emulsion.
- 1,3-butylene glycol 50 polyoxyethylene (10) methylglucose 02 glyceryl tri-2-ethylhexanoate 75 0 squalane 20
- a mixture obtained by mixing and dissolving the following components (1) to (9) and (12) and (17) is mixed with the components (10), (11), (13) to (16) and (18) to (24). ) was added to the mixture obtained by mixing and dissolving, and the mixture was mixed to obtain a lotion.
- a mixture in which the following components (1) to (10) were mixed and dissolved was added to and mixed with the mixed and dissolved components (11 to (21)) to obtain a cloudy lotion.
- a mixture obtained by mixing and dissolving the components (1) to (4), (6) and (7) at 50 ° C, and the components (8) to (13) and (25) are heated and mixed at 50 ° C.
- the components (1) to (10) were heated and mixed at 70 ° C. and dispersed in a slurry. This The components (11) to (13) and (15) to (22) were dissolved and mixed at 50 ° C., and the component (14) was added to obtain a sunscreen emulsion.
- Components (1) to (9) were heated and mixed at 70 ° C. Add the components (10) to (13) and (15) to (20), which are heated and mixed at 50 ° C, and add the component (14) to add a water-in-oil type sunscreen. I got a cream.
- the components (1) to (8) are heated and mixed at 70 ° C, and the components (9) to (16) and (18) to (25) heated and mixed at 50 ° C are added and mixed.
- Component (17) was added to obtain a water-in-oil cream.
- the following components (1) to (7) are heated and mixed, and the components (13) and (18) are added to this mixture, mixed and maintained at 70 ° C. Add the above mixture to components (8) to (12) mixed and kept at 70 ° C, and emulsify uniformly. After cooling, the components (1 9) to (25 ) was added to obtain a liquid foundation.
- Examples 8 to 21 All of the cosmetics obtained in Examples 11 and 12 have excellent stability over time, and can be applied to the skin to prevent dullness of the skin due to sunburn, spots and freckles, and wrinkles and sagging due to aging. Various cosmetics that were excellent in improving effect and made transparent and beautiful skin.
- B16 melanoma cultured cells from mice were used. An appropriate amount of a MEM medium containing 10% FBS was taken in two 6-well plates, B16 melanoma cells were inoculated, and allowed to stand at 37 ° C and a carbon dioxide concentration of 5 Vo 1%. The next day, the Cistus 1 adaniferus L. extract obtained in Example 1 and the labdenoic acids and their methyl and ethyl esters obtained in Example 2 were combined with final concentrations of 0 (control), 5, 10 ⁇ g / mL, A sample preparation solution was added to and mixed with Kanzo II extract (manufactured by Maruzen Pharmaceutical Co., Ltd.) as a whitening agent so as to obtain 0,100 gZmL.
- Kanzo II extract manufactured by Maruzen Pharmaceutical Co., Ltd.
- the medium On the fifth day of the culture, the medium was replaced, and the sample preparation solution was added again. On the next day, the medium was removed, and the cells of one plate were washed with a phosphate buffer (pH 7) and collected, and the whitening degree of the B16 melanoma cultured cells was evaluated according to the following criteria.
- the okuinin extract was obtained by adding 10 OmL of 70 V o 1% aqueous ethyl alcohol to 10 g of okuinin (JP), extracting at room temperature for 3 days, and then filtering. At this time, the dry solid content of the extract was 0.8%.
- Soil slightly white compared to control.
- the cells were fixed in formalin, and stained by adding 1% crystal violet solution. Cell viability for each sample concentration was measured with a monocellator (Olympus). The results are shown in Table 1-2.
- Example 23 Method for producing black ryant (Krofusadari) fruit extract 10 g of black ryant (Ribesnigrum L ⁇ ) fruit was crushed, and 50 vo 1% aqueous ethyl alcohol 10 OmL was added thereto. After extraction for one day, the resultant was filtered to obtain a fruit extract of black power plant (Kurofusasudari) (dry solid content: 2.4%).
- the fruit of Ayasufashima (A inusfirma Sieb. Et Zucc.) Contains 10 OmL of 50 vol% water-containing ethyl alcohol per l Og, extracted at room temperature for 3 days, and then filtered to remove the Yashaji extract. (Dry solid content 1.0%).
- the components (1) to (6) were mixed, and the mixture heated and maintained at 70 ° C was mixed with the component (16) heated and maintained at 70 ° C. Further, after mixing the components (7) to (15), the mixture was cooled to obtain a cream.
- a panel of 15 women aged 27 to 54 for each test cream Apply an appropriate amount of the test cream to the face after washing the face twice daily, 12 weeks, in the morning and at night.
- the evaluation was based on criteria.
- the evaluation results are Indicated by the number of people in the panel
- Human neonatal fibroblasts NB 1 RGB were used. An appropriate amount of the medium was placed in a 24-well plate, and fibroblast NB1RGB was inoculated and allowed to stand at 37 ° C in a carbon dioxide concentration of 5 vol 1%. The next day, the Cistusladaniferus L. extract obtained in Example 1 and the labdenoic acids and their methyl esters and ethyl ester obtained in Example 2 were added at final concentrations of 0 (control), 5, 1 O jug / mL, and cell activation. The sample preparation was added and mixed so that the saboten extract as an agent was 0 and 100 g / mL. The culture medium was replaced on the fourth day of culture, and the sample preparation solution was added again. On the next day, the medium was removed, the cells were washed with a phosphate buffer, and the cells were collected. The number of fibroblasts NB1RGB grown in each sample preparation was evaluated as the cell growth rate as compared to the control.
- soybean extract (lOOgZmL), which is already known as having a cell activating effect as a comparative example.
- the soybean extract was obtained by adding 10 OmL of 70 V o 1% aqueous ethyl alcohol to 10 g of soybean seeds, extracting at room temperature for 3 days, and then filtering. At this time, the dry solid content of the soybean extract was 0.5%.
- Example 29 As is clear from the results in Table 3-2, it was confirmed that the plant extract had a cell activating ability against NB1RGB, a fibroblast derived from newborn human However, it was found that when a cactus extract as a cell activator was used in combination, the cell activator had a better cell activator ability. Therefore, the cell activator of the present invention is extremely effective by applying to the skin a mixture of Cistusladaniferus L. extract and labdenoic acid and its methyl ester, and ethyl ester and cactus extract. It is expected to exhibit excellent anti-aging effect and to effectively improve skin wrinkles and sagging caused by aging, exposure to ultraviolet rays, etc.
- the components (1) to (6) were mixed, and a part of the component (16) heated and maintained at 70 ° C was added to the mixture heated and maintained at 70 ° C.
- the components (7) to (15) were mixed with the mixture, and then cooled to obtain a cream.
- a panel of 20 women aged 35 to 59 per test cream was applied to the face twice daily, morning and night, for 12 weeks after washing the face.
- the wrinkle improvement effect of the coating was evaluated according to the following criteria.
- the following components (1) to (10) were heated and mixed at 70 ° C.
- the components (11) to (13), (22) and (25), which were heated and mixed at 70 ° C, were added to this mixture and mixed, and the components (14) to (21), (23) ) And (24) were added and mixed, and the mixture was cooled to room temperature to obtain a cream.
- Titanium oxide 0 Dipropylene glycol 0 0
- the following components (1) to (8) are heated and mixed at 70 ° C, and components (9) to (16) and (18) to (21) heated and mixed at 50 ° C are added thereto. After mixing, the component (17) was added to obtain a water-in-oil cream.
- Each of the creams obtained in Examples 34 and 35 has excellent stability over time, and can be applied to the skin to make the skin dull due to sunburn, stains and freckles, and These creams are excellent in preventing and improving wrinkles and sagging due to aging, and are transparent and beautiful skin.
- the obtained facial cleanser was excellent in stability over time, and was applied to the skin to give a clear and beautiful skin.
- the mixture obtained by mixing and dissolving the following components (1) to (9) and (12) and (16) is mixed with the components (10), (11), (13) to (15) and (17) to (21). ) And mixed to obtain a cosmetic water.
- the mixture obtained by mixing and dissolving the following components (1) to (9) was mixed with (10) and (16) by calo; a lotion was obtained.
- a mixture in which the following components (1) to (10) were mixed and dissolved was added to and mixed with the mixed and dissolved components (11) to (19) to obtain a cloudy lotion.
- the following components (1) to (11) were heated and mixed at 70 ° C. and dispersed in a slurry.
- the components (12) to (14) and (16) to (20) were dissolved and mixed at 50 ° C, and the component (15) was added to obtain a sunscreen emulsion.
- the components (7) to (12) and (19) were heated and mixed at 50 ° C, and cooled to room temperature to prepare a mixture.
- Each of the cosmetics obtained in Examples 37 to 47 has excellent stability over time and can be applied to the skin to prevent dullness of the skin due to sunburn, spots and freckles, and wrinkles and sagging due to aging.
- Industrial applicability As described above, according to the present invention, it is possible to provide an external preparation for skin that is excellent in skin whitening effect, especially whitening and Z or anti-aging effect.
- This excellent effect is a synergistic effect obtained by using the compound represented by the general formula (1) in combination with a specific component, and the compound represented by the general formula (1) is used alone. It has a remarkably excellent skin, whitening and / or anti-aging effect that cannot be obtained when used in the above or when a specific component is used alone.
- R 1 represents _CH 2 OH or COOR 6
- R 6 represents hydrogen, a lower alkyl group having 1 to 3 carbon atoms or a cation capable of forming a salt with COO— 2 to R 5 each independently represent a hydrogen atom or a methyl group
- the (B) power (B1) asparagus extract, corn extract, soybean extract, senuki extract, eiji extract, raspberry extract, kujin extract, squid extract, coffee extract, Komenu power extract, Wheat germ extract, Saishin extract, Hawthorn extract, Shirahuri extract, Peony extract, Tea extract, Molasses extract, Grape extract, Hop extract, Maikai power extract, Mokka extract , Wagon extract, seaweed extract, dibutylhydroxytoluene, butylhydroxyesonore, mannitol, ⁇ -carotene, quenorecetin, que / resitrin, / retin, vitamin, and derivatives thereof, gennoshoko extract, saxifrage extract Extract, Melissa extract, glycyrrhizic acid and its derivatives, Richirurechin Acids and their derivatives, Vitamin B and its derivatives, Gentian extract, Dokudami extract, Button extract, Aloe extract, Alniki extract, O
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gerontology & Geriatric Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/531,289 US20060147397A1 (en) | 2002-11-07 | 2003-07-30 | Composition for preparation for external use on skin and method of using the same |
AU2003252305A AU2003252305A1 (en) | 2002-11-07 | 2003-07-30 | Composition for preparation for external use on skin and method of using the same |
EP03810579A EP1570839B1 (en) | 2002-11-07 | 2003-07-30 | Composition for preparation for external use on skin and method of using the same |
DE60322101T DE60322101D1 (de) | 2002-11-07 | 2003-07-30 | Zusammensetzungzur herstellung zur äusserlichen anwendung auf der haut sowie verfahren zu ihrer verwendung |
HK06102824.2A HK1082916A1 (en) | 2002-11-07 | 2006-03-03 | Composition for preparation for external use on skin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-323503 | 2002-11-07 | ||
JP2002323503A JP4091825B2 (ja) | 2002-02-05 | 2002-11-07 | 皮膚外用剤 |
JP2002-323502 | 2002-11-07 | ||
JP2002323502A JP4091824B2 (ja) | 2002-02-05 | 2002-11-07 | 皮膚外用剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004041236A1 true WO2004041236A1 (ja) | 2004-05-21 |
Family
ID=32314061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/009651 WO2004041236A1 (ja) | 2002-11-07 | 2003-07-30 | 皮膚外用剤用組成物およびその使用方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060147397A1 (ja) |
EP (1) | EP1570839B1 (ja) |
KR (1) | KR100970544B1 (ja) |
AU (1) | AU2003252305A1 (ja) |
DE (1) | DE60322101D1 (ja) |
HK (1) | HK1082916A1 (ja) |
TW (1) | TWI280138B (ja) |
WO (1) | WO2004041236A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2856299A1 (fr) * | 2003-06-19 | 2004-12-24 | Tagasako Internat Corp | Composition promotrice de la synthese cellulaire du collagene, utilisation en therapeutique, cosmetique et alimentation |
WO2007105706A1 (ja) * | 2006-03-14 | 2007-09-20 | Kose Corporation | 美白用皮膚外用剤及び皮膚の美白方法 |
CN101155576B (zh) * | 2005-04-13 | 2012-02-08 | 株式会社资生堂 | 抗皱剂 |
CN103054027A (zh) * | 2013-01-11 | 2013-04-24 | 太原市澳意医药生物科技有限公司 | 芦荟蜂花方便粒 |
CN103054028A (zh) * | 2013-01-11 | 2013-04-24 | 太原市澳意医药生物科技有限公司 | 芦荟膳食纤维方便粒 |
CN103054039A (zh) * | 2013-01-11 | 2013-04-24 | 太原市澳意医药生物科技有限公司 | 芦荟阿胶方便粒 |
CN101584722B (zh) * | 2008-05-20 | 2013-06-12 | 佰研生化科技股份有限公司 | 一种改善老化皮肤的草本组合物 |
WO2015145602A1 (ja) * | 2014-03-26 | 2015-10-01 | 株式会社コーセー | 皮膚外用剤または化粧料として有用な組成物 |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100697235B1 (ko) | 2005-07-13 | 2007-03-22 | 한국생명공학연구원 | 관동화 추출물 또는 투실라곤을 포함하는 비만 및 제2형당뇨병 예방 및 치료용 조성물 |
KR100848382B1 (ko) | 2006-05-08 | 2008-07-24 | 서명숙 | 미용조성물 및 이용한 퍼머액 |
KR100773856B1 (ko) * | 2006-06-02 | 2007-11-06 | 주식회사 바이오랜드 | 나한과 추출물 또는 이로부터 분리된 트라이터펜계화합물을 함유하는 주름개선용 조성물 |
FR2902334B1 (fr) * | 2006-06-16 | 2011-09-30 | Nuxe Lab | Utilisation d'un extrait de souci dans une composition cosmetique. |
AU2007269790A1 (en) * | 2006-06-30 | 2008-01-10 | Tyco Healthcare Group, Lp | Wound closure adhesive remover |
US20090035398A1 (en) * | 2007-03-29 | 2009-02-05 | Raymond Williams | Topical formulations |
KR100842169B1 (ko) * | 2007-05-10 | 2008-06-27 | 대구보건대학산학협력단 | 차조기와 황금, 포황 추출물을 첨가한 비누 및 그 제조방법 |
CN101687106B (zh) * | 2007-06-01 | 2015-04-29 | 盖尔德马研究及发展公司 | 新型保湿剂及其用途 |
US7722904B2 (en) * | 2007-11-01 | 2010-05-25 | Access Business Group International Llc | Compositions and methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid |
DE102008012068A1 (de) * | 2008-02-29 | 2009-09-10 | Henkel Ag & Co. Kgaa | Haarbehandlungsmittel mit Cranberry-Extrakt |
EP2295028A4 (en) * | 2008-03-31 | 2013-11-13 | Shiseido Co Ltd | PREPARATION FOR PREVENTING OR REDUCING WRINKLES FOR ORAL INJECTION, FOR INJECTION OR FOR EXTERNAL APPLICATION TO THE SKIN AND COSMETIC PROCEDURE |
DE102008022392A1 (de) * | 2008-05-06 | 2009-11-12 | Evonik Goldschmidt Gmbh | Kosmetika enthaltend Zistrosenkraut-Extrakte |
US20100034763A1 (en) * | 2008-08-05 | 2010-02-11 | Conopco, Inc., D/B/A Unilever | Skin Lightening Composition Comprising CO2 Extracts |
EP2588070B8 (en) | 2010-06-30 | 2019-07-24 | Société des Produits Nestlé S.A. | USE OF CHICORIC ACID AND LACTIC BACTERIUM IN FOOD SUPPLEMENT FOR lightening and/or whitening skin tone |
JP2013530996A (ja) * | 2010-06-30 | 2013-08-01 | ネステク ソシエテ アノニム | 皮膚の色素沈着を調節するための、栄養補助食品におけるカフタル酸及び誘導体の使用 |
JP2013530995A (ja) * | 2010-06-30 | 2013-08-01 | ネステク ソシエテ アノニム | 皮膚の色素沈着を調節するための、栄養補助食品におけるチコリ酸及び誘導体の使用 |
KR101850165B1 (ko) * | 2010-06-30 | 2018-04-18 | 네스텍 소시에테아노님 | 피부 색소침착 조절용 식품 보충제에 있어서 카프타르산 및 락틱 박테리아의 용도 |
KR101788359B1 (ko) | 2010-12-30 | 2017-11-15 | 마리 케이 인코포레이티드 | 다목적 화장품 조성물 |
CN108403521B (zh) * | 2011-03-28 | 2022-02-11 | 玫琳凯有限公司 | 局部皮肤用组合物及其用途 |
US8454943B2 (en) | 2011-04-06 | 2013-06-04 | Mary Kay Inc. | Topical skin care formulations comprising plant extracts |
US20150118334A1 (en) * | 2012-06-17 | 2015-04-30 | Kamedis Ltd | Topical compositions for the treatment of chronic inflammatory skin disease |
FR3025424B1 (fr) * | 2014-09-05 | 2016-12-23 | Soc Ind Limousine D'application Biologique | Principe actif obtenu a partir de calendula officinalis et utilisation dans la prevention et le traitement de manifestations cutanees dues a un dereglement de l'epigenome dans les cellules de la peau |
SG11201802551WA (en) | 2015-12-07 | 2018-04-27 | Otsuka Pharma Factory Inc | Skin disinfectant composition |
US10543243B2 (en) | 2016-06-06 | 2020-01-28 | Charsire Biotechnology Corp. | Soybeam seed extract, method for producing the same and uses thereof |
KR101869956B1 (ko) * | 2016-10-20 | 2018-06-21 | 농업회사법인주식회사니파바이오 | 니파야자 꽃대를 이용한 마스크 팩 |
KR20180065514A (ko) | 2016-12-08 | 2018-06-18 | 사조동아원 주식회사 | 밀 배아로 부터 2,6-dmbq의 추출방법 |
KR101944633B1 (ko) | 2017-11-09 | 2019-01-31 | 사조동아원 주식회사 | 효소첨가된 밀 배아로 부터 2,6-디메톡시-ρ-벤조퀴논 증가 추출방법 |
KR102119316B1 (ko) * | 2018-09-27 | 2020-06-04 | 주식회사 인투바이오 | 모란 복합추출물을 함유하는 화장료 조성물 |
KR102209208B1 (ko) * | 2019-09-25 | 2021-01-29 | 주식회사 코스메카코리아 | 오스톨 유효성분을 함유하는 벌사상자 발아 추출물 제조방법 및 이를 유효성분으로 함유하는 미백 화장료 조성물 |
US11166999B1 (en) * | 2020-08-18 | 2021-11-09 | Morehouse School Of Medicine | Method of treating coronavirus infections |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07206654A (ja) * | 1994-01-14 | 1995-08-08 | Pola Chem Ind Inc | メラニン産生抑制剤及び皮膚外用剤 |
JPH09291011A (ja) * | 1996-04-24 | 1997-11-11 | Kose Corp | 外用に適する組成物 |
JPH1160467A (ja) * | 1997-08-15 | 1999-03-02 | Takasago Internatl Corp | メラニン産生抑制剤 |
EP0970693A1 (en) * | 1998-04-20 | 2000-01-12 | Takasago International Corporation | Biologically active labdane or labdene derivatives from Cistus |
WO2001026670A1 (fr) * | 1999-10-14 | 2001-04-19 | The Nisshin Oil Mills, Ltd. | Agents de soin de la peau, agents anti-ages pour la peau, agents de blanchiment de la peau et preparations pour la peau, a usage externe |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3568771D1 (en) * | 1984-10-10 | 1989-04-20 | Givaudan & Cie Sa | Hexanoates, process for their preparation and perfumes and/or flavouring agents having a content of such compounds |
RU2026683C1 (ru) * | 1993-05-19 | 1995-01-20 | Игорь Электринович Острейковский | Состав для лечения ожирения |
JPH07238059A (ja) * | 1994-02-25 | 1995-09-12 | Kao Corp | 新規なラブデノイック酸エチルエステル及びこれを含有する香料組成物 |
IL109012A (en) * | 1994-03-17 | 1998-09-24 | Fischer Pharma Ltd | Skin whitening composition comprising glycyrrhyza glabra and hydroxy acids |
ES2107976B1 (es) * | 1996-05-27 | 1998-07-01 | Angui Emilio Rodriguez | Locion capilar y procedimiento para su fabricacion. |
DE19821971C2 (de) * | 1998-05-18 | 2003-02-06 | Ulti Med Products Deutschland | Arzneimittel zur Behandlung von Psoriasis oder Neurodermitis |
KR20010057585A (ko) * | 1999-12-24 | 2001-07-04 | 고바야시 레이지로 | 피부외용제 |
-
2003
- 2003-07-30 WO PCT/JP2003/009651 patent/WO2004041236A1/ja active IP Right Grant
- 2003-07-30 KR KR1020057008088A patent/KR100970544B1/ko active IP Right Grant
- 2003-07-30 US US10/531,289 patent/US20060147397A1/en not_active Abandoned
- 2003-07-30 AU AU2003252305A patent/AU2003252305A1/en not_active Abandoned
- 2003-07-30 DE DE60322101T patent/DE60322101D1/de not_active Expired - Lifetime
- 2003-07-30 EP EP03810579A patent/EP1570839B1/en not_active Expired - Lifetime
- 2003-08-01 TW TW092121200A patent/TWI280138B/zh not_active IP Right Cessation
-
2006
- 2006-03-03 HK HK06102824.2A patent/HK1082916A1/xx not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07206654A (ja) * | 1994-01-14 | 1995-08-08 | Pola Chem Ind Inc | メラニン産生抑制剤及び皮膚外用剤 |
JPH09291011A (ja) * | 1996-04-24 | 1997-11-11 | Kose Corp | 外用に適する組成物 |
JPH1160467A (ja) * | 1997-08-15 | 1999-03-02 | Takasago Internatl Corp | メラニン産生抑制剤 |
EP0970693A1 (en) * | 1998-04-20 | 2000-01-12 | Takasago International Corporation | Biologically active labdane or labdene derivatives from Cistus |
WO2001026670A1 (fr) * | 1999-10-14 | 2001-04-19 | The Nisshin Oil Mills, Ltd. | Agents de soin de la peau, agents anti-ages pour la peau, agents de blanchiment de la peau et preparations pour la peau, a usage externe |
Non-Patent Citations (1)
Title |
---|
See also references of EP1570839A4 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2856299A1 (fr) * | 2003-06-19 | 2004-12-24 | Tagasako Internat Corp | Composition promotrice de la synthese cellulaire du collagene, utilisation en therapeutique, cosmetique et alimentation |
CN101155576B (zh) * | 2005-04-13 | 2012-02-08 | 株式会社资生堂 | 抗皱剂 |
WO2007105706A1 (ja) * | 2006-03-14 | 2007-09-20 | Kose Corporation | 美白用皮膚外用剤及び皮膚の美白方法 |
CN101400333B (zh) * | 2006-03-14 | 2012-05-09 | 株式会社高丝 | 美白用皮肤外用剂以及皮肤的美白方法 |
JP5399701B2 (ja) * | 2006-03-14 | 2014-01-29 | 株式会社コーセー | 美白用皮膚外用剤及び皮膚の美白方法 |
CN101584722B (zh) * | 2008-05-20 | 2013-06-12 | 佰研生化科技股份有限公司 | 一种改善老化皮肤的草本组合物 |
CN103054027A (zh) * | 2013-01-11 | 2013-04-24 | 太原市澳意医药生物科技有限公司 | 芦荟蜂花方便粒 |
CN103054028A (zh) * | 2013-01-11 | 2013-04-24 | 太原市澳意医药生物科技有限公司 | 芦荟膳食纤维方便粒 |
CN103054039A (zh) * | 2013-01-11 | 2013-04-24 | 太原市澳意医药生物科技有限公司 | 芦荟阿胶方便粒 |
WO2015145602A1 (ja) * | 2014-03-26 | 2015-10-01 | 株式会社コーセー | 皮膚外用剤または化粧料として有用な組成物 |
JPWO2015145602A1 (ja) * | 2014-03-26 | 2017-04-13 | 株式会社コーセー | 皮膚外用剤または化粧料として有用な組成物 |
Also Published As
Publication number | Publication date |
---|---|
DE60322101D1 (de) | 2008-08-21 |
KR100970544B1 (ko) | 2010-07-16 |
TW200413021A (en) | 2004-08-01 |
EP1570839A4 (en) | 2006-06-28 |
EP1570839A1 (en) | 2005-09-07 |
TWI280138B (en) | 2007-05-01 |
EP1570839B1 (en) | 2008-07-09 |
AU2003252305A1 (en) | 2004-06-07 |
US20060147397A1 (en) | 2006-07-06 |
HK1082916A1 (en) | 2006-06-23 |
KR20050084971A (ko) | 2005-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004041236A1 (ja) | 皮膚外用剤用組成物およびその使用方法 | |
JP3958968B2 (ja) | 皮膚外用剤及び美白剤 | |
JP4091825B2 (ja) | 皮膚外用剤 | |
JP4091824B2 (ja) | 皮膚外用剤 | |
KR101857528B1 (ko) | 금화규 추출물을 함유하는 피부 미백용 화장료 조성물 | |
JP2005220084A (ja) | アセロラ種子抽出物含有組成物 | |
WO2001026670A1 (fr) | Agents de soin de la peau, agents anti-ages pour la peau, agents de blanchiment de la peau et preparations pour la peau, a usage externe | |
JP2007210915A (ja) | 皮膚外用剤 | |
JP2012001467A (ja) | 皮膚外用剤 | |
JP2003063925A (ja) | 皮膚外用剤 | |
JP3987793B2 (ja) | 皮膚外用剤 | |
JP3704498B2 (ja) | 皮膚外用剤 | |
JP3754646B2 (ja) | 皮膚外用剤 | |
JP4035481B2 (ja) | 皮膚外用剤 | |
JP2004051492A (ja) | 老化防止剤又は細胞賦活剤及びこれを含有する皮膚外用剤 | |
KR100535875B1 (ko) | 피부 미백 효과를 갖는 식물 혼합 추출물을 함유하는화장료 조성물 | |
JP2002275081A (ja) | 皮膚外用剤 | |
JP4203325B2 (ja) | 皮膚外用剤及び皮膚外用剤組成物 | |
JP2003252742A (ja) | メラノサイト樹状突起形成抑制剤及びこれを含有する皮膚外用剤 | |
JP2007238597A (ja) | 皮膚外用剤 | |
KR101854766B1 (ko) | 미백 효능을 갖는 트리히드록시 이소플라본 및 감초 추출물의 복합체 | |
JP2006176440A (ja) | 皮膚の美白ないしは老化防止剤組成物および化粧品 | |
JP2004067549A (ja) | 皮膚外用剤 | |
JP2009256326A (ja) | 美白剤、及び皮膚外用剤 | |
JP2003321377A (ja) | 老化防止剤及びそれを用いた皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020057008088 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003810579 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038255774 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057008088 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003810579 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006147397 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10531289 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10531289 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003810579 Country of ref document: EP |